Biovian sponsors ESGCT Helsinki
Press Release | Biovian Ltd
SEPTEMBER 15, 2015
Turku, Finland: – Specialist biopharmaceutical CMO Biovian will once again field a high powered team at next week’s European Society of Gene and Cell Therapy meeting in Helsinki.
Biovian is a Silver sponsor in of the ESGCT conference 2015, which is a four day event opening September 17th.
Gene to finished vial
Biovian will also be an exhibitor at the event with a booth in Helsinki’s striking Finlandia Hall.
Biovian´s Business Development Director Antti Nieminen will lead the Finnish-based manufacturer’s presence at ESCGT and will be available for one-to-one meetings and to share news of latest developments in Biovian’s distinctive “gene to finished vial” end-to-end cGMP service.
Biovian Ltd. is a one-stop-shop Contract Manufacturing Organization (CMO) specializing in full-process development and manufacture that extends ‘from gene to finished vial’.
Biovian offers Good Manufacturing Practice compliant (cGMP) services from its 2,700 square meter facilities in Turku, Finland, that are EMA and FDA certified for production of investigational and commercial products.
The CMO has more than a decade’s successful track record in pharmaceutical contract manufacturing ranging over a wide variety of different biopharmaceutical projects. Biovian GMP services include microbial fermentation, mammalian cell culture, viral vector production, protein purification, formulation, aseptic fill & finish, analytical quality control, stability studies and master cell banking. It also offers labeling, packaging, storage and QP release services.
Biovian also provides development services that cover cell line, process and analysis.
About ESCGT 2015
The European Society of Gene and Cell Therapy (ESGCT) is an organization committed to support scientists and clinicians involved with basic and translational research on gene transfer and clinical applications of gene and cell therapy.
The society’s annual congress provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. The event currently attracts more than 1,000 delegates from some 40 countries worldwide.
The 2015 event is a four-day meeting held September 17-20 at the Alvar Aalto-designed, Finlandia Hall in Helsinki. Nobel Prize winner Prof. Stefan Hell will lead an eminent list of speakers.
ESGCT 2015 is organised in collaboration with the Finnish Society of Gene Therapy. More information at: http://www.esgct.eu/Home.aspx
Name: Antti Nieminen, Director, Business Development and Projects, Biovian Ltd.
Tel:+358 40 5021332